Description: NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden.
Home Page: www.nextcellpharma.com
Karolinska Institutet Science Park
Huddinge,
141 57
Sweden
Phone:
46 87 35 55 95
Officers
| Name | Title |
|---|---|
| Dr. Mathias Svahn Ph.D. | Founder & CEO |
| Mr. Patrik Fagerholm | Chief Financial Officer |
| Mr. Lindsay Davies | Chief Scientific Officer |
| Mr. Edvard Smith | Medical Director & Director |
| Sofie Falk Jansson | Head of Cellaviva |
| Ms. Sofia Sisay | Head of Clinical Trials |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4166 |
| Price-to-Sales TTM: | 0.9868 |
| IPO Date: | |
| Fiscal Year End: | August |
| Full Time Employees: | 0 |